Lannett Company, Inc. (NYSE:LCI) CEO Timothy C. Crew bought 3,000 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was acquired at an average cost of $6.85 per share, for a total transaction of $20,550.00. Following the completion of the purchase, the chief executive officer now directly owns 47,758 shares in the company, valued at $327,142.30. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
LCI stock opened at $6.15 on Monday. The company has a market cap of $269.74 million, a PE ratio of 1.98 and a beta of 2.40. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.88 and a current ratio of 2.88. Lannett Company, Inc. has a one year low of $3.33 and a one year high of $17.15.
Lannett (NYSE:LCI) last released its quarterly earnings results on Monday, May 6th. The company reported $0.68 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.06. The firm had revenue of $172.79 million for the quarter, compared to analyst estimates of $155.55 million. Lannett had a negative net margin of 39.84% and a positive return on equity of 25.79%. The business’s revenue for the quarter was down .9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.80 EPS. Analysts forecast that Lannett Company, Inc. will post 2.18 earnings per share for the current year.
A number of research analysts have weighed in on the stock. ValuEngine lowered shares of Lannett from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. Zacks Investment Research raised shares of Lannett from a “sell” rating to a “hold” rating in a research report on Wednesday, January 16th. Finally, SunTrust Banks assumed coverage on shares of Lannett in a research report on Tuesday, March 19th. They set a “hold” rating and a $9.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a strong buy rating to the stock. Lannett currently has an average rating of “Hold” and an average target price of $19.45.
WARNING: This article was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/05/13/insider-buying-lannett-company-inc-lci-ceo-buys-20550-00-in-stock.html.
Lannett Company Profile
Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.
Recommended Story: Why do companies pay special dividends?
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.